STOCK TITAN

Tyra Biosciences (TYRA) DEF 14A Filings

TYRA NASDAQ

Here are the DEF 14A proxy statements from Tyra Biosciences, Inc. (TYRA) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow TYRA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TYRA filings page.

Rhea-AI Summary

Tyra Biosciences, Inc. is asking stockholders to vote at a fully virtual 2026 Annual Meeting on May 28, 2026. Holders of Common Stock at the close of business on April 2, 2026, when 59,485,237 shares were outstanding, are entitled to vote.

Stockholders will vote on electing three Class II directors—Habib J. Dable, Susan Moran, M.D., M.S.C.E., and Robert More—for terms expiring at the 2029 annual meeting, and on ratifying Ernst & Young LLP as independent registered public accounting firm for 2026. The Board recommends voting in favor of all nominees and the auditor ratification.